Healthcare leaders have renewed pressure on policymakers to overhaul how treatment rates are set, saying reimbursement must be grounded in scientific costing studies rather than broad estimates or legacy package prices. Hospital executives argue that the current framework often fails to capture the real expense of delivering quality care, especially in an environment where medical inflation, imported equipment costs, staffing needs and compliance requirements continue to rise.
Costing Gap Widens
Industry executives say the central problem is not merely that rates are low, but that they are often disconnected from the economics of modern hospital operations. A treatment package that may have been viable several years ago can quickly become unworkable when adjusted for higher salaries, consumables, diagnostics, energy costs and the expense of maintaining clinical standards. In their view, reimbursement systems that do not reflect these changes create a structural gap between policy intent and operational reality.
The concern is particularly acute in tertiary and super-specialty care, where hospitals must invest heavily in advanced technology, infection control, trained personnel and round-the-clock clinical readiness. Executives warn that if reimbursement remains below actual delivery cost, hospitals may be forced to cross-subsidise government-supported care through private patients, reduce investment in capacity, or avoid offering certain procedures altogether. That, they say, would undermine the broader objective of expanding affordable access.
Scientific Pricing Needed
Healthcare leaders are calling for a more rigorous methodology to determine rates, including periodic scientific costing studies that account for the full lifecycle of care delivery. Such studies, they argue, should measure direct clinical costs as well as indirect overheads, depreciation, maintenance, quality assurance and the cost of regulatory compliance. They also want a transparent mechanism for updating rates regularly so that reimbursement does not become obsolete by the time it is implemented.
The demand reflects a wider debate in India's health economy over how to balance affordability for patients with financial sustainability for providers. Publicly funded health schemes have expanded access to hospital care, but hospital associations have repeatedly said that package rates often do not keep pace with actual expenses. The result, they argue, is a system in which providers are expected to deliver increasingly complex care at prices that may be closer to historical benchmarks than to present-day costs.
Executives also point out that pricing distortions can affect clinical behaviour. If reimbursement is too low, hospitals may be incentivised to shorten stays, limit the use of newer technologies or shift patients toward procedures that are financially less strained. Over time, they say, this can create inefficiencies and compromise the quality of care. A scientifically derived pricing model, by contrast, would allow hospitals to plan better, invest more confidently and maintain standards without depending on opaque internal subsidies.
Policy Stakes Rise
The issue has broader fiscal implications for the government as well. Any upward revision in treatment rates would increase the cost of publicly funded healthcare programmes, but executives argue that underpricing simply transfers the burden elsewhere in the system. Hospitals absorb losses, patients face uneven access, and the state risks building a reimbursement architecture that looks efficient on paper but is fragile in practice.
For policymakers, the challenge is to design a framework that is both financially disciplined and medically credible. That likely means more granular costing, stronger consultation with providers and a willingness to differentiate between basic, secondary and advanced care rather than applying a one-size-fits-all approach. It may also require clearer recognition that quality care is not costless and that pricing systems must evolve alongside medical practice.
The debate arrives at a time when healthcare is increasingly central to India's macroeconomic and fiscal agenda. Rising demand for care, an ageing population, and the growing burden of non-communicable diseases are all pushing up system costs. Against that backdrop, hospital leaders say the question is not whether reimbursement should be controlled, but whether it should be scientifically grounded. Their answer is unequivocal: without realistic costing, healthcare pricing will remain misaligned with the true economics of care delivery.